Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a final ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the European Medicines Agency's (EMA) Committee for ...

EMA committee recommends marketing approval of Pfizer & BioNTech’s LP.8.1-adapted Covid-19 vaccine: New York Saturday, July 26, 2025, 10:00 Hrs [IST] Pfizer Inc. and BioNTech SE ...

Adam Levav blinds us with science in a neat Saturday debut.

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 202 ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Ryan Richardson will step down as Chief Strategy Officer in the Management Board of BioNTech on September 30, 2025, and as ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...